Tanvex BioPharma, Inc.
Research Tanvex BioPharma, Inc. (6541.TW) on Bullrun: market cap TWD 8.11B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker6541.TW
- ExchangeTW
- CountryCayman Islands
- SectorHealthcare
- IndustryBiotechnology
- CurrencyTWD
- Market capTWD 8.11B
- Financial periodQ2 2026
- RevenueTWD 220.44M
- Net income-TWD 382.53M
- Free cash flow-TWD 282.94M
- Gross margin-102.5%
Valuation Snapshot
latest market cap is TWD 8.11B.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | TWD 8.11B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 TWD.
About Tanvex BioPharma, Inc.
Tanvex BioPharma, Inc., a pharmaceutical company, engages in the research, development, manufacture, and sale of biosimilar products in Taiwan and the United States. The company focuses on delivering biopharmaceuticals with biosimilars targeting neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. It also engages in contract development and manufacturing of biological medicines. The company was founded in 2011 and is headquartered in George Town, the Cayman Islands.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Tanvex BioPharma, Inc.'s market cap?
Tanvex BioPharma, Inc.'s market capitalization is TWD 8.11B.
What does Tanvex BioPharma, Inc. do?
Tanvex BioPharma, Inc., a pharmaceutical company, engages in the research, development, manufacture, and sale of biosimilar products in Taiwan and the United States. The company focuses on delivering biopharmaceuticals with biosimilars targeting neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. It also engages in contract development and manufacturing of biological medicines. The company was founded in 2011 and is headquartered in George Town, the Cayman Islands.